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Despite the small number of patients studied, these results suggest the importance of limiting the prescription of 25 OH D3 to children suffering from renal osteodystrophy only after having assessed unequivocally an osteomalacic component by histodynamical criteria. Secondary hyperparathyroidism appears not to be improved with moderate doses of 25 OH D3 in the absence of adequate serum phosphorus control.
M E T H O D S
PLASMA BIO ('t{EMISTRY All blood samples were obtained immediately before dialysis. Total plasma calcium was measured by atomic spectrophotometry (Perkin Elmer). plasma phosphorus, and alkaline phosphatases ( I ) with autoanalyzer (Technicon. Daumont. France). Serum iPTH levels were measured by radioimmunoassay using a guineapig antibody (GP6) and identifying the carboxy terminal of PTH (2, 5) . Serum 25-hydroxy vitamin D (25 O H D ) concentrations were measured using a radiocompetitive protein binding assay (18) .
RADIOLOGIC E V A L U A T I O N
The subperiostal resorption was looked for on X-ray examinations of the vhalanaes and the skull. Osteomalacia was assessed . , on radiograms of the wrist and the tibiae and osteosclerosis on the Speculation third lumbar vertebra. Bone maturity was measured according to Treatment with 25 OH D3 may be justified for the treatment of Greulich and 'yle ( I I). chronic hemodialyzed children with definite osteomalacia a s a component of their renal osteodystrophy. Secondary hyperpara- 19-yr-old . were included in this study. All pm thick, were used for the analysis of tetracycline labels. under presented with renal osteodystrophy as estimated by clinical and fluorescent light. radiologic data, serum immunoreactive parathyroid hormone
The following parameters were measured: I ) Trabecular bone (iPTH) levels and histologic criteria (Tables 1-3 ). Details of these volume (T.B.V.) that represents the fraction of the cancellous bone findings have been given elsewhere (8, 12) . They were dialyzed volume occupied by bone matrix (%). 2) Trabecular osteoclastic for 5 hr three times a week using a calcium dialysate of 1.75 resorption surface (T.O.R.S.), that represents the percent of the mmole/liter. Before treatment with 25 O H D3, each child was total trabecular bone surface occupied by resorption sites (that given daily 25 mmole ( I g) of calcium. 125 nmole (2000 IU) of notch the trabecular edges) (%). We did not distinguish between vitamin D2, and 7.5-1 1.5 mmole (600-900 mg) of aluminium "active" and "inactive" resorption surfaces. according to the preshydroxide.
ence or absence of osteoclasts in the Howship's lacunae. 3) NumThe synthetic 25 O H D3 (Laboratoires Roussel, Paris, France) ber of osteoclasts per mm2 of bone tissue (section) (Ocl./mm2). 4) was given orally, once a day during 8 months. Seventy-five nmole Trabecular osteoid volume (T.O.V.) that represents the percent of (30 pg) of 25 O H D3 were administered, daily during the first 3 a given volume of the trabecular bone occupied by osteoid (TO). 5) 7) Calcification rate (C.R.) was evaluated in cancellous bone by measuring the mean distance between the two fluorescent labels on each site of active calcification (10).
RESULTS

CLINICAL A N D RADIOLOGIC RESULTS
The five children had no deformities, bone pain, or epiphysiolysis. Growth retardation was present in three cases (patients 1-3) (Table I ) and 25 O H D3 had little effect on growth velocity that never exceeded 3 cm/yr. There were no extraosseous calcifications, except conjunctival calcifications that were revealed on slit lamp examination at the beginning of treatment in three children (patients [3] [4] [5] and were present at the end of the study in four cases (patients 1, 2, 4, 5) . Subperiostal resorption was noted in four cases (patients 1 4 ) and osteosclerosis in two (patients 3, 4) . No change of these radiologic signs was noted as a n affect of the treatment. Classical radiologic signs of osteomalacia or rickets were never observed. Bone age increased by I yr in two of the children during the study (patients 1, 2).
BIOLOGIC RESULTS (TABLE 2 A N D FIGURE I )
Plasma calcium, phosphorus, and alkaline phosphatase were checked regularly every month and the results are given in Figure  1 . Plasma calcium remained within the normal range during the treatment, except in one child who had transient hypercalcemia (patient 2). In this case, treatment was temporarily discontinued. Plasma phosphate levels were elevated in all cases despite aluminium hydroxide, and there was no consistent change in serum phosphorus concentrations after 25 O H D3, except in patient 3 whose plasma levels returned to within the normal range after 6 months of treatment. Plasma alkaline phosphatase concentrations were initially elevated in three children (patients 1, 2, and 3) and returned gradually to within normal range. Plasma iPTH increased in the five children, but the variation of the mean level was not significant ( P < 0.1). Circulating 25 O H D levels were all normal before the study and rose significantly ( P < 0.001) in every case.
HISTOMORPHOMETRIC RESULTS (TABLE 3)
At the beginning of the study, all five children had histomorphometric abnormalities. The classical signs of hyperparathyroidism (increase of the trabecular osteoclastic resorption surfaces and of the number of osteoclasts per mm') were seen to varying degrees in all five cases. With the treatment, hyperparathyroid signs did ' This SD is an approximation taking into account the intraobserver error and the sampling variation. not change significantly. Osteomalacia, defined by an increase in the thickness index of the osteoid seams and decrease of the calcification rate (13), was present on the initial bone biopsy of only one patient ( I ) and improved with the treatment.
In the four other cases, the increase of the trabecular osteoid surfaces without modification of the calcification rate and of the thickness index, did not indicate osteomalacia, but only hyperparathyroidism, according to previous studies (13). Under the treatment, the trabecular osteoid surfaces increased in all these cases, while the calcification rate decreased. As the thickness index remained unchanged, the decrease in calcification rate was only due to a decrease in osteoblastic appositional rate, in other words, to a decrease in the rate of synthesis of new collagen by osteoblasts.
The trabecular bone volume was initially increased in two children (patients 3 and 4) and decreased in a third child (patient 5). Under the treatment, the trabecular bone volume diminished in the two patients with osteosclerosis. The surface of bone section occupied by woven bone decreased markedly under treatment. This decrease was assessed on qualitative criteria because the quantification of woven bone is imprecise.
DISCUSSION
Few studies have been made on the treatment of dialysis bone disease with 25 OH D3 (9, 19.21) and only one concerned children (21) . Antirachitic effect with pharmacologic doses of 25 OH D3 has been previously demonstrated in renal osteodystrophy (3, 7, 9. 19. 2 I) . Moderate doses of this drug administered over a short period of time improved calcification-front (7) . It has been suggested that 25 OH D3 in physiologic concentrations can have an effect on bone mineralization in chronic renal failure (6) . Eight anephric patients have shown no histologic evidence of osteomalacia up to 6 yr after bilateral nephrectomy (3). Eastwood et al. (6) noted a defect of mineralization only in-patients with chronic renal failure in whom plasma 25 OHD levels were low. However, this result was not confirmed in another study (15) . It seems possible that 25 OH D3 is directly involved in active mineralization. The selective incorporation of tritiated 25 OH D3 in epiphyseal cartilage and bone growing rats has been reported (20) .
Hypercalcemia may be seen during 25 OH D3 treatment. This disorder required, in a previous study, an interruption of the treatment and several injections of calcitonin; in one case, subtotal parathyroidectomy was performed (21) .
The improvement of hyperparathyroidism is less evident. A drop in serum iPTH levels was absent in this study and insignificant in others (7, 9) . Hyperphosphoremia prevents perhaps this decrease (9) . A rise in phosphoremia has been previously reported during treatment with 25 OH D3 (9) or I-a-hydroxycholecalciferol (9, 16) . It may be explained by an increase in the intestinal absorption of phosphate, demonstrated during treatment with I a-hydroxycholecalciferol (16) . In this study, secondary hyperparathyroidism and its prints on bone tissue, noted in all five children, did not improve in the absence of adequate serum phosphorus control. However, controversial results have been reported with a decrease in circulating iPTH (19) and in hyperparathyroidism bone lesions (19, 21) . In these studies. plasma phosphorus levels were variable (21) or not reported (19) . In addition. it is possible that, in these cases, the doses of 25 OH D3 used might not have been large enough because serum 25 OHD levels failed to rise above 135-250 nmole/liter during the treatment.
Furthermore, cancellous bone volume diminished in two patients with the administration of 25 OH D3. This was noted in a previous study (21) . This activity of the drug could be related to its inhibitory effect of osteoblastic apposition. The inhibition of osteob~astic~a~position is demonstrated in our cases by the decrease in the calcification rates, while the thickness index of the osteoid seams remains normal. This fact coincides with a marked decrease of the areas occupied by woven bone. Woven bone is 
